GeoVax Labs (NASDAQ:GOVX) Stock to Reverse Split on Wednesday, November 11th

Shares of GeoVax Labs Inc. (NASDAQ:GOVX) are set to reverse split before the market opens on Wednesday, November 11th. The 1-24 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, November 10th.

GeoVax Labs Price Performance

Shares of NASDAQ GOVX traded down $0.03 during midday trading on Tuesday, reaching $0.11. 1,296,066 shares of the stock traded hands, compared to its average volume of 1,786,974. The stock has a market capitalization of $821,755.00, a PE ratio of -0.01 and a beta of 3.85. The company’s 50 day moving average is $0.32 and its 200 day moving average is $1.19. GeoVax Labs has a one year low of $0.11 and a one year high of $13.00.

Analyst Ratings Changes

Several analysts have issued reports on GOVX shares. Noble Financial reaffirmed an “outperform” rating on shares of GeoVax Labs in a research report on Tuesday, September 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Thursday, October 15th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, GeoVax Labs currently has a consensus rating of “Hold” and a consensus price target of $150.00.

GeoVax Labs Company Profile

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. The company’s technology platform is based primarily on modified vaccinia Ankara (MVA) and virus-like particle (VLP) vaccine technologies, which are designed to generate broad and durable immune responses. GeoVax’s pipeline has included GEO-CM04S1, a multivalent COVID-19 vaccine candidate intended to address emerging coronavirus variants, as well as investigational vaccines for HIV, hemorrhagic fever viruses such as Ebola and Marburg, and other infectious diseases.